- Home
- OXSQ vs ACIU Comparison
OXSQ vs ACIU Comparison
Compare OXSQ & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXSQ
- ACIU
- Stock Information
- Founded
- OXSQ 2003
- ACIU 2003
- Country
- OXSQ United States
- ACIU Switzerland
- Employees
- OXSQ N/A
- ACIU N/A
- Industry
- OXSQ Blank Checks
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- OXSQ Finance
- ACIU Health Care
- Exchange
- OXSQ Nasdaq
- ACIU Nasdaq
- Market Cap
- OXSQ 164.9M
- ACIU 168.7M
- IPO Year
- OXSQ N/A
- ACIU 2016
- Fundamental
- Price
- OXSQ $2.21
- ACIU $1.88
- Analyst Decision
- OXSQ
- ACIU Strong Buy
- Analyst Count
- OXSQ 0
- ACIU 1
- Target Price
- OXSQ N/A
- ACIU $12.00
- AVG Volume (30 Days)
- OXSQ 567.4K
- ACIU 115.4K
- Earning Date
- OXSQ 08-12-2025
- ACIU 08-05-2025
- Dividend Yield
- OXSQ 19.05%
- ACIU N/A
- EPS Growth
- OXSQ N/A
- ACIU N/A
- EPS
- OXSQ N/A
- ACIU N/A
- Revenue
- OXSQ $42,166,831.00
- ACIU $32,014,254.00
- Revenue This Year
- OXSQ N/A
- ACIU N/A
- Revenue Next Year
- OXSQ N/A
- ACIU $533.21
- P/E Ratio
- OXSQ N/A
- ACIU N/A
- Revenue Growth
- OXSQ N/A
- ACIU 91.20
- 52 Week Low
- OXSQ $2.19
- ACIU $1.43
- 52 Week High
- OXSQ $3.10
- ACIU $4.41
- Technical
- Relative Strength Index (RSI)
- OXSQ 22.78
- ACIU 51.75
- Support Level
- OXSQ $2.26
- ACIU $1.83
- Resistance Level
- OXSQ $2.33
- ACIU $2.10
- Average True Range (ATR)
- OXSQ 0.03
- ACIU 0.15
- MACD
- OXSQ -0.00
- ACIU -0.00
- Stochastic Oscillator
- OXSQ 13.33
- ACIU 44.44
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.